Compare CFFN & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | MPLT |
|---|---|---|
| Founded | 1893 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 981.1M | 1.2B |
| IPO Year | 2010 | N/A |
| Metric | CFFN | MPLT |
|---|---|---|
| Price | $7.79 | $30.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.25 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 858.4K | 275.5K |
| Earning Date | 04-29-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $16,300,000.00 | N/A |
| Revenue This Year | $20.16 | N/A |
| Revenue Next Year | $6.62 | N/A |
| P/E Ratio | $24.25 | ★ N/A |
| Revenue Growth | ★ 6.54 | N/A |
| 52 Week Low | $5.51 | $12.24 |
| 52 Week High | $7.97 | $33.28 |
| Indicator | CFFN | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 56.53 |
| Support Level | $7.47 | $26.70 |
| Resistance Level | $7.84 | $32.68 |
| Average True Range (ATR) | 0.17 | 2.80 |
| MACD | -0.01 | -0.50 |
| Stochastic Oscillator | 60.22 | 49.93 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.